CN113423401A - 使用布鲁顿氏酪氨酸激酶抑制剂来治疗类风湿性关节炎、慢性自发性荨麻疹和系统性红斑狼疮的方法 - Google Patents

使用布鲁顿氏酪氨酸激酶抑制剂来治疗类风湿性关节炎、慢性自发性荨麻疹和系统性红斑狼疮的方法 Download PDF

Info

Publication number
CN113423401A
CN113423401A CN202080010603.3A CN202080010603A CN113423401A CN 113423401 A CN113423401 A CN 113423401A CN 202080010603 A CN202080010603 A CN 202080010603A CN 113423401 A CN113423401 A CN 113423401A
Authority
CN
China
Prior art keywords
patient
treatment
dose
fenebrutinib
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080010603.3A
Other languages
English (en)
Chinese (zh)
Inventor
胜本多美子
L·钦
A·莫里莫托
D·J·哈登
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Priority to CN202410639156.8A priority Critical patent/CN118453606A/zh
Priority to CN202410640589.5A priority patent/CN118662512A/zh
Publication of CN113423401A publication Critical patent/CN113423401A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202080010603.3A 2019-01-22 2020-01-21 使用布鲁顿氏酪氨酸激酶抑制剂来治疗类风湿性关节炎、慢性自发性荨麻疹和系统性红斑狼疮的方法 Pending CN113423401A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202410639156.8A CN118453606A (zh) 2019-01-22 2020-01-21 使用布鲁顿氏酪氨酸激酶抑制剂来治疗类风湿性关节炎、慢性自发性荨麻疹和系统性红斑狼疮的方法
CN202410640589.5A CN118662512A (zh) 2019-01-22 2020-01-21 使用布鲁顿氏酪氨酸激酶抑制剂来治疗类风湿性关节炎、慢性自发性荨麻疹和系统性红斑狼疮的方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962795477P 2019-01-22 2019-01-22
US62/795,477 2019-01-22
US201962913270P 2019-10-10 2019-10-10
US62/913,270 2019-10-10
PCT/US2020/014346 WO2020154252A1 (en) 2019-01-22 2020-01-21 Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton's tyrosine kinase

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202410640589.5A Division CN118662512A (zh) 2019-01-22 2020-01-21 使用布鲁顿氏酪氨酸激酶抑制剂来治疗类风湿性关节炎、慢性自发性荨麻疹和系统性红斑狼疮的方法
CN202410639156.8A Division CN118453606A (zh) 2019-01-22 2020-01-21 使用布鲁顿氏酪氨酸激酶抑制剂来治疗类风湿性关节炎、慢性自发性荨麻疹和系统性红斑狼疮的方法

Publications (1)

Publication Number Publication Date
CN113423401A true CN113423401A (zh) 2021-09-21

Family

ID=69726724

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202080010603.3A Pending CN113423401A (zh) 2019-01-22 2020-01-21 使用布鲁顿氏酪氨酸激酶抑制剂来治疗类风湿性关节炎、慢性自发性荨麻疹和系统性红斑狼疮的方法
CN202410640589.5A Pending CN118662512A (zh) 2019-01-22 2020-01-21 使用布鲁顿氏酪氨酸激酶抑制剂来治疗类风湿性关节炎、慢性自发性荨麻疹和系统性红斑狼疮的方法
CN202410639156.8A Pending CN118453606A (zh) 2019-01-22 2020-01-21 使用布鲁顿氏酪氨酸激酶抑制剂来治疗类风湿性关节炎、慢性自发性荨麻疹和系统性红斑狼疮的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202410640589.5A Pending CN118662512A (zh) 2019-01-22 2020-01-21 使用布鲁顿氏酪氨酸激酶抑制剂来治疗类风湿性关节炎、慢性自发性荨麻疹和系统性红斑狼疮的方法
CN202410639156.8A Pending CN118453606A (zh) 2019-01-22 2020-01-21 使用布鲁顿氏酪氨酸激酶抑制剂来治疗类风湿性关节炎、慢性自发性荨麻疹和系统性红斑狼疮的方法

Country Status (11)

Country Link
US (1) US12544372B2 (https=)
EP (1) EP3914250A1 (https=)
JP (3) JP2022523018A (https=)
KR (1) KR20210119457A (https=)
CN (3) CN113423401A (https=)
AU (2) AU2020213265B2 (https=)
CA (1) CA3125236A1 (https=)
IL (1) IL284779A (https=)
MX (2) MX2021008696A (https=)
TW (1) TW202042815A (https=)
WO (1) WO2020154252A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021249129A1 (en) 2020-04-03 2022-10-20 F. Hoffmann-La Roche Ag Methods of treating relapsing Multiple Sclerosis using an inhibitor of Bruton's tyrosine kinase
WO2024235166A1 (zh) * 2023-05-12 2024-11-21 武汉人福创新药物研发中心有限公司 含有btk抑制剂的组合物及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103189074A (zh) * 2010-11-05 2013-07-03 诺华有限公司 使用il-17拮抗剂治疗类风湿性关节炎的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
EP4049660B1 (en) 2016-02-29 2025-02-19 F. Hoffmann-La Roche AG Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase
JP2020514384A (ja) 2017-03-24 2020-05-21 ジェネンテック， インコーポレイテッド 自己免疫及び炎症性疾患を治療する方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103189074A (zh) * 2010-11-05 2013-07-03 诺华有限公司 使用il-17拮抗剂治疗类风湿性关节炎的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JAMES J. CRAWFORD ET AL.: ""Discovery of GDC-0853, a Potent, Selective, and Non-Covalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development"", 《JOURNAL OF MEDICINAL CHEMISTRY》, vol. 61, no. 6, pages 2227 - 2245 *

Also Published As

Publication number Publication date
AU2020213265A1 (en) 2021-07-22
MX2025013950A (es) 2026-03-02
IL284779A (en) 2021-08-31
MX2021008696A (es) 2021-08-19
TW202042815A (zh) 2020-12-01
KR20210119457A (ko) 2021-10-05
WO2020154252A1 (en) 2020-07-30
CN118662512A (zh) 2024-09-20
AU2020213265B2 (en) 2025-01-16
AU2025201888A1 (en) 2025-04-03
JP2022523018A (ja) 2022-04-21
CA3125236A1 (en) 2020-07-30
US12544372B2 (en) 2026-02-10
JP2026041743A (ja) 2026-03-10
EP3914250A1 (en) 2021-12-01
US20220047588A1 (en) 2022-02-17
CN118453606A (zh) 2024-08-09
JP2024099575A (ja) 2024-07-25

Similar Documents

Publication Publication Date Title
Katarzyna et al. Current treatment of systemic lupus erythematosus: a clinician's perspective
Abbasi et al. Strategies toward rheumatoid arthritis therapy; the old and the new
Genovese et al. LY2439821, a humanized anti–interleukin‐17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double‐blind, placebo‐controlled, proof‐of‐concept study
JP2026041743A (ja) ブルトン型チロシンキナーゼの阻害剤を使用する関節リウマチ、慢性自発性蕁麻疹、および全身性エリテマトーデスの処置方法
Daien et al. Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine
Lustig et al. Use of immunosuppressive agents in uveitis
Kant et al. Principles of immunosuppression in the management of kidney disease: core curriculum 2022
CN118948848A (zh) 用于治疗免疫缺陷病的方法
KR20220163986A (ko) 브루톤 티로신 키나아제의 억제제를 이용한 재발성 다발성 경화증의 치료 방법
CN116406296A (zh) 狼疮发作的治疗
CN115667309A (zh) 使用i型干扰素信号传导的抑制剂治疗心血管代谢疾病
HK40056367A (en) Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton’s tyrosine kinase
US20230091561A1 (en) Methods of treating primary progressive multiple sclerosis using an inhibitor of bruton's tyrosine kinase
Greenzaid et al. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Moderate-to-Severe Psoriasis: J. Greenzaid et al.
Castañeda et al. Adult-onset Still's disease
Koh et al. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy
Neycheva et al. IL-17 Inhibitor secukinumab achieves remission in relapsing polychondritis: A case report
TADA et al. New Therapy in Rheumatoid Arthritis Biological DMARDs and JAK Inhibitors
Ibrahim et al. Advances in Treatment of Juvenile Idiopathic Arthritis
Raje et al. EVALUATING PATIENTS WITH RECURRENT FEVER AND ELEVATED IGD
Olson et al. Conjunctival eosinophilic granulomatosis with polyangiitis (Churg-Strauss) in a young adult male with persistent ptosis
Erwig et al. ANCA-associated vasculitides: advances in pathophysiology and treatment
Teaford A NOVEL PATHOGENIC VARIANT IN CTLA-4 ASSOCIATED WITH AUTOINFLAMMATION AND RESPONSE TO ABATACEPT AND DUPILUMAB
Raed Alzyoud., et al.“Unicentric Castleman’s Disease with Multicentric Behavior: A Case Report”
CN121127499A (zh) 狼疮的治疗

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40056367

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210921

WD01 Invention patent application deemed withdrawn after publication